07:00 , Apr 18, 2016 |  BC Week In Review  |  Clinical News

BTA585: Phase IIa started

Aviragen (formerly Biota Pharmaceuticals Inc. ) began a double-blind, placebo-controlled, U.K. Phase IIa trial to evaluate 100 mg oral BTA585 twice daily for 7 days in about 60 healthy adult volunteers challenged intranasally with RSV....
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

BTA585: Phase I data

Top-line data from a placebo-controlled, U.S. Phase I trial in 36 healthy volunteers showed that twice-daily 100, 400 and 600 mg doses of oral BTA585 were generally well tolerated with no serious adverse events reported....
08:00 , Feb 15, 2016 |  BC Week In Review  |  Clinical News

BTA074: Phase II started

Biota began a double-blind, placebo-controlled, South American Phase II trial to evaluate topical BTA074 5% gel twice daily for up to 16 weeks in about 210 patients with anogenital warts caused by HPV types 6...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

BTA585: Phase I started

Last month, Biota began a placebo-controlled Phase I trial to evaluate 100, 400 and 600 mg oral BTA585 twice daily in 36 healthy volunteers. Biota Pharmaceuticals Inc. (NASDAQ:BOTA), Alpharetta, Ga.   Product: BTA585   Business:...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

BTA585: Phase I data

Top-line data from a blinded, placebo-controlled, U.S. Phase I trial in 50 healthy volunteers showed that single doses of 50, 100, 200, 400 and 500 mg oral BTA585 were generally well tolerated with no serious...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

BTA585: Phase I started

Biota began a placebo-controlled, dose-escalation Phase I trial to evaluate 5 single doses of 50-500 mg oral BTA585 in about 50 healthy volunteers. Next quarter, the company plans to start a Phase I trial to...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

Anaconda Pharma, Biota Pharmaceuticals deal

Biota completed its acquisition of Anaconda for $8 million in cash and 3.5 million Biota shares, valued at $7.5 million based on Biota’s close of $2.15 on June 2, before the deal closed (see BioCentury,...
07:00 , Jun 4, 2015 |  BC Innovations  |  Translation in Brief

If it FtsZ

Taxis Pharmaceuticals Inc. has rescued a series of compounds in development limbo through a deal with Biota Pharmaceuticals Inc. (NASDAQ:BOTA), and used the molecules to create a preclinical first-in-class antibiotic that kills Gram-positive bacteria by...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Company News

Anaconda Pharma, Biota Pharmaceuticals deal

Biota is acquiring Anaconda for $8 million in cash and 3.5 million Biota shares, valued at $8.7 million based on Biota’s close of $2.48 on Feb. 25, before the deal was announced. Anaconda shareholders are...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Clinical News

Vapendavir: Phase IIb started

Biota began the double-blind, placebo-controlled, dose-ranging, international Phase IIb SPIRITUS trial to evaluate 264 and 528 mg oral vapendavir twice daily for 7 days in about 150 patients with moderate to severe asthma and HRV...